The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
-
REGULATORY Reference Pricing on Agenda for CEFP Social Security Working Group
March 10, 2017
-
BUSINESS Pfizer’s FY2016 Japan Sales Slide 7.4% on Price Cuts, Generic Erosions
March 9, 2017
-
REGULATORY MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
March 8, 2017
-
REGULATORY Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
-
COMMENTARY Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
-
INTERVIEW Chugai to Execute Area-Based Strategy Centering on General Reps: Marketing Chief
March 6, 2017
-
BUSINESS Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President
March 3, 2017
-
REGULATORY 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
-
ORGANIZATION EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
-
INTERVIEW Daiichi Sankyo Espha Eyes 50 Billion Yen Sales in 2020 with AGs as Growth Engine
February 28, 2017
-
BUSINESS Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
-
INTERVIEW Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki
February 24, 2017
-
REGULATORY Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
-
REGULATORY CEFP Working Group to Go Full Throttle on Policy Guidelines Debate in March
February 22, 2017
-
REGULATORY New Formats for Package Inserts to Be Announced in April, Enforced from FY2019 with Transition Period: MHLW
February 21, 2017
-
ACADEMIA AMED Drafts Japan’s First Manual for Treatment of Mitochondrial Diseases
February 20, 2017
-
REGULATORY MHLW Advisory Panel to Review Shionogi’s ADHD Drug on March 2
February 17, 2017
-
TRENDS Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands
February 16, 2017
-
REGULATORY With Eye to June Listing, 24 Generic Makers Flock to Micardis Family, 15 to Abilify
February 16, 2017
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…